PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.160
-0.070 (-5.69%)
At close: Aug 13, 2025, 4:00 PM
1.180
+0.020 (1.72%)
Pre-market: Aug 14, 2025, 8:46 AM EDT
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,525,091
Market Cap
53.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PDSB News
- 23 hours ago - PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 8 days ago - PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - GlobeNewsWire
- 2 months ago - PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - GlobeNewsWire
- 2 months ago - PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 3 months ago - PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - GlobeNewsWire